Reduced Levels of Anti-MDA LDL Antibodies in Patients with Carbohydrate Metabolism Disorders

Lourdes Garrido-Sánchez; JM García-Pinilla; Jim, M.énez-Navarro; Fern, J.ández-Pastora; Juan H Alonso-Briales; Jose M Hernández-Garcia; Eduardo de-Teresa-Galván; Francisco J Tinahones

Clinical Laboratory 57(11-12): 901-907

2011


ISSN/ISBN: 1433-6510
PMID: 22239020
Document Number: 14566
Background: Diabetic patients undergoing percutaneous coronary intervention (PCI) have a worse prognosis than non-diabetic patients. The anti-oxidized LDL antibodies (anti-LDLox ab) have recently been suggested to be protective against the development of diabetes. The aim of this study was to compare the levels of IgG and IgM antioxidized LDL antibodies with reference to the new diagnostic criteria for carbohydrate metabolism disorders after an oral glucose tolerance test (OGTT) in hospitalized patients scheduled to undergo percutaneous coronary intervention. Methods: We undertook a cross-sectional study of 110 patients undergoing PCI. The patients were classified as being normal (oral glucose test tolerance normal, OGTT-N), or having impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM) according to their glucose levels at baseline and after an OGTT. Results: An inverse slope was found in the levels of IgG anti-oxidized LDL antibodies between the OGTT-N patients (optical density (OD) = 0.109) and the patients with IGT (OD = 0.099) or T2DM (OD = 0.084) (p = 0.019). An inverse correlation was also detected between the levels of IgG anti-oxidized LDL antibodies and baseline glycemia (r = -0.23, p = 0.018). Conclusions: Patients with coronary disease and carbohydrate metabolism disorders have much lower levels of IgG anti-oxidized LDL antibodies than normoglycemic patients.

Document emailed within 1 workday
Secure & encrypted payments

Reduced Levels of Anti-MDA LDL Antibodies in Patients with Carbohydrate Metabolism Disorders